219 related articles for article (PubMed ID: 27684979)
21. Plasmablastic lymphoma mimicking carcinomatosis: A case report and review of the literature.
Olofson AM; Loo EY; Hill PA; Liu X
Diagn Cytopathol; 2017 Mar; 45(3):243-246. PubMed ID: 27900846
[TBL] [Abstract][Full Text] [Related]
22. Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.
Guedez L; Martinez A; Zhao S; Vivero A; Pittaluga S; Stetler-Stevenson M; Raffeld M; Stetler-Stevenson WG
Blood; 2005 Feb; 105(4):1660-8. PubMed ID: 15479729
[TBL] [Abstract][Full Text] [Related]
23. Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma.
Ahn JS; Okal R; Vos JA; Smolkin M; Kanate AS; Rosado FG
J Clin Pathol; 2017 Sep; 70(9):775-780. PubMed ID: 28249941
[TBL] [Abstract][Full Text] [Related]
24. Plasmablastic lymphoma: a clinicopathologic correlation.
Folk GS; Abbondanzo SL; Childers EL; Foss RD
Ann Diagn Pathol; 2006 Feb; 10(1):8-12. PubMed ID: 16414538
[TBL] [Abstract][Full Text] [Related]
25. Immunophenotypic features by multiparameter flow cytometry can help distinguish low grade B-cell lymphomas with plasmacytic differentiation from plasma cell proliferative disorders with an unrelated clonal B-cell process.
Rosado FG; Morice WG; He R; Howard MT; Timm M; McPhail ED
Br J Haematol; 2015 May; 169(3):368-76. PubMed ID: 25644063
[TBL] [Abstract][Full Text] [Related]
26. CD31 expression in plasmacytic/plasmablastic lesions.
Plocharczyk E; Wakely PE
Ann Diagn Pathol; 2013 Dec; 17(6):498-501. PubMed ID: 24074836
[TBL] [Abstract][Full Text] [Related]
27. Plasmablastic lymphoma of the stomach in an HIV-negative patient.
Hashimoto M; Inaguma S; Kasai K; Kuwabara K; Noda N; Hayakawa M; Fujino M; Ito M; Ikeda H
Pathol Int; 2012 Nov; 62(11):763-70. PubMed ID: 23121609
[TBL] [Abstract][Full Text] [Related]
28. Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome.
Simonitsch-Klupp I; Hauser I; Ott G; Drach J; Ackermann J; Kaufmann J; Weltermann A; Greinix HT; Skrabs C; Dittrich C; Lutz D; Pötter R; Mannhalter C; Lechner K; Chott A; Jaeger U
Leukemia; 2004 Jan; 18(1):146-55. PubMed ID: 14603341
[TBL] [Abstract][Full Text] [Related]
29. [Clinicopathologic features of lymphoplasmacytic lymphoma].
Liu EB; Zhang PH; Li ZQ; Sun Q; Yang QY; Fang LH; Sun FJ; Qiu LG
Zhonghua Bing Li Xue Za Zhi; 2010 May; 39(5):308-12. PubMed ID: 20654153
[TBL] [Abstract][Full Text] [Related]
30. Lineage determination of CD20- B-Cell neoplasms: an immunohistochemical study.
Chu PG; Loera S; Huang Q; Weiss LM
Am J Clin Pathol; 2006 Oct; 126(4):534-44. PubMed ID: 16938666
[TBL] [Abstract][Full Text] [Related]
31. Peroxiredoxin I is differentially expressed in multiple myelomas and in plasmablastic lymphomas.
Demasi AP; Magalhães MH; Furuse C; Araújo NS; Junqueira JL; Araújo VC
Oral Dis; 2008 Nov; 14(8):741-6. PubMed ID: 18565146
[TBL] [Abstract][Full Text] [Related]
32. The biology and treatment of plasmablastic lymphoma.
Castillo JJ; Bibas M; Miranda RN
Blood; 2015 Apr; 125(15):2323-30. PubMed ID: 25636338
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic uses of Pax5 immunohistochemistry.
Feldman AL; Dogan A
Adv Anat Pathol; 2007 Sep; 14(5):323-34. PubMed ID: 17717432
[TBL] [Abstract][Full Text] [Related]
34. Plasmablastic lymphoma in an elderly immunocompetent patient.
Takeuchi M; Ogawa F; Onishi T; Moriyama Y
Pathol Int; 2012 May; 62(5):347-50. PubMed ID: 22524665
[TBL] [Abstract][Full Text] [Related]
35. Use of an expanded immunohistochemical panel to distinguish cutaneous Hodgkin lymphoma from histopathologic imitators.
Cho RJ; McCalmont TH; Ai WZ; Fox LP; Treseler P; Pincus LB
J Cutan Pathol; 2012 Jun; 39(6):651-8. PubMed ID: 22324490
[TBL] [Abstract][Full Text] [Related]
36. Uniform expression of Notch1, suppressor of B-cell-specific gene expression, in plasmablastic lymphoma.
Seegmiller AC; Wang HY; Hladik C; Chen W
Arch Pathol Lab Med; 2011 Jun; 135(6):770-5. PubMed ID: 21631271
[TBL] [Abstract][Full Text] [Related]
37. Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course?
Beltran BE; Quiñones P; Sanchez G; Paredes A; Moises C; Cotrina E; Torres-Cabala CA; Miranda RN; Castillo JJ
Leuk Lymphoma; 2018 Jul; 59(7):1753-1755. PubMed ID: 29081245
[No Abstract] [Full Text] [Related]
38. [Clinical characteristics and survival analysis of eight cases HIV-negative plasmablastic lymphoma].
Han X; Hu LX; Ouyang MQ; Duan MH; Zhou DB
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):290-294. PubMed ID: 28468089
[No Abstract] [Full Text] [Related]
39. PAX-5 is invariably expressed in B-cell lymphomas without plasma cell differentiation.
Dong HY; Browne P; Liu Z; Gangi M
Histopathology; 2008 Sep; 53(3):278-87. PubMed ID: 18643853
[TBL] [Abstract][Full Text] [Related]
40. Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy.
Pretscher D; Kalisch A; Wilhelm M; Birkmann J
Ann Hematol; 2017 Jun; 96(6):967-970. PubMed ID: 28011983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
